113 related articles for article (PubMed ID: 7105056)
1. Phase II trial of bisantrene for advanced hypernephroma.
Scher H; Schwartz S; Yagoda A; Watson R; Faye L
Cancer Treat Rep; 1982 Aug; 66(8):1653-5. PubMed ID: 7105056
[No Abstract] [Full Text] [Related]
2. Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma.
Evans WK; Shepherd FA; Blackstein ME; Osoba D; Taylor D
Cancer Treat Rep; 1985 Jun; 69(6):727-8. PubMed ID: 4016779
[No Abstract] [Full Text] [Related]
3. Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.
Taylor SA; Von Hoff DD; Baker LH; Balcerzak SP
Cancer Treat Rep; 1984 Jun; 68(6):919-20. PubMed ID: 6733708
[No Abstract] [Full Text] [Related]
4. Phase II trial of bisantrene in advanced colorectal cancer: a cancer and leukemia group B study.
Perry MC; Forastiere AA; Richards F; Weiss RB; Anbar D
Cancer Treat Rep; 1982 Nov; 66(11):1997-8. PubMed ID: 7139643
[No Abstract] [Full Text] [Related]
5. Phase II trial of diaziquone in advanced renal adenocarcinoma.
Hansen M; Gallmeier WM; Vermorken J; Holdener E; Hansen HH; Renard J; Rozencweig M
Cancer Treat Rep; 1984; 68(7-8):1055-6. PubMed ID: 6744342
[No Abstract] [Full Text] [Related]
6. Phase II trial of bisantrene in patients with advanced sarcoma: a Southwest Oncology Group Study.
Cowan JD; Gehan E; Rivkin SE; Jones SE
Cancer Treat Rep; 1986 May; 70(5):685-6. PubMed ID: 3708622
[No Abstract] [Full Text] [Related]
7. Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma.
Elson PJ; Earhart RH; Kvols LK; Spiegel R; Keller AM; Kies MS; Davis TE; Stevens C; Gumas L; Trump DL
Cancer Treat Rep; 1987 Mar; 71(3):331-2. PubMed ID: 3815401
[No Abstract] [Full Text] [Related]
8. Phase II trial of spirogermanium in advanced renal cell carcinoma: a Cancer and Leukemia Group B study.
Schulman P; Davis RB; Rafla S; Green M; Henderson E
Cancer Treat Rep; 1984 Oct; 68(10):1305-6. PubMed ID: 6525606
[No Abstract] [Full Text] [Related]
9. Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinoma.
Van Echo DA; Markus S; Aisner J; Wiernik PH
Cancer Treat Rep; 1980; 64(8-9):1009-10. PubMed ID: 6893810
[No Abstract] [Full Text] [Related]
10. Phase II trial of elliptinium in advanced renal cell carcinoma and carcinoma of the breast.
Sternberg CN; Yagoda A; Casper E; Scoppetuolo M; Scher HI
Anticancer Res; 1985; 5(4):415-7. PubMed ID: 4037737
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen in unresectable hypernephroma. A phase II trial and review of the literature.
Weiselberg L; Budman D; Vinciguerra V; Schulman P; Degnan TJ
Cancer Clin Trials; 1981; 4(2):195-8. PubMed ID: 7249256
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
Myers JW; Von Hoff DD; Clark GM; Coltman CA
Cancer Treat Rep; 1984 Jun; 68(6):927-8. PubMed ID: 6329511
[No Abstract] [Full Text] [Related]
13. Treatment of advanced non-small cell lung cancer with bisantrene.
Fuks JZ; Van Echo DA; Garbino C; Kasdorf H; Aisner J
Cancer Treat Rep; 1983 Jun; 67(6):597-8. PubMed ID: 6305499
[No Abstract] [Full Text] [Related]
14. Phase II evaluation of bisantrene in patients with renal cell carcinoma.
Myers JW; Von Hoff DD; Coltman CA; Kuhn JG; Van Echo D; Rivkin S; Pocelinko R
Cancer Treat Rep; 1982 Oct; 66(10):1869-71. PubMed ID: 7127326
[No Abstract] [Full Text] [Related]
15. Treatment of advanced adenocarcinoma of the kidney with ICRF-187: a Southeastern Cancer Study Group Trial.
Brubaker LH; Vogel CL; Einhorn LH; Birch R
Cancer Treat Rep; 1986 Jul; 70(7):915-6. PubMed ID: 3087618
[No Abstract] [Full Text] [Related]
16. Phase II study of vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer.
Hahn RG; Begg CB; Davis T
Cancer Treat Rep; 1981; 65(7-8):711-13. PubMed ID: 7018680
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of bisantrene administered by continuous 72-hour infusion for advanced pancreatic adenocarcinoma.
Marschke RF; Kvols LK; Cullinan SA; Laurie JA; Mailliard JA; Tschetter LK; O'Connell MJ
Med Pediatr Oncol; 1988; 16(4):269-70. PubMed ID: 3419393
[TBL] [Abstract][Full Text] [Related]
18. Bisantrene in non-small cell lung cancer: a phase II trial of the Cancer and Leukemia Group B.
Green MR; Vosika G; Propert KJ; Ware JH; Comis R
Cancer Treat Rep; 1986 Apr; 70(4):539-40. PubMed ID: 3698052
[No Abstract] [Full Text] [Related]
19. Phase II trial of bisantrene in previously treated patients with ovarian carcinoma: a Southwest Oncology Group Study.
Cowan JD; Surwit EA; Alberts DS; Boutselis JG; Neilan BA
Cancer Treat Rep; 1986 Mar; 70(3):423-4. PubMed ID: 3955558
[No Abstract] [Full Text] [Related]
20. Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic hypernephroma.
Schneider RJ; Woodcock TM; Yagoda A
Cancer Treat Rep; 1980 Jan; 64(1):183-5. PubMed ID: 6892892
[No Abstract] [Full Text] [Related]
[Next] [New Search]
